Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype.

Molecular genetics and metabolism 2020 Feb

filter terms:

Knowledge on clinical profiles of late-onset phenotypes of Fabry disease (FD) is essential to better define their natural history. Our study aims to demonstrate a founder effect of FD due to the GLA gene mutation c.337T>C (p.F113L) in the Portuguese region of Guimarães; and to characterize the clinical profile of this late-onset phenotype in a large cohort of genetically related adult patients, living in the same region. FD screening was performed in 150 adult patients with hypertrophic cardiomyopathy (HCM) and found 25 Fabry patients (16.6%). The p.F113L mutation was found in 21 of them, leading to a genealogy study and haplotype analysis of the p.F113L patients. Genealogy research revealed a 12-generation family tree with a common ancestor to p.F113L patients, suggesting a founder effect that was supported by haplotype findings. Pedigree analysis was performed and 120 consecutive p.F113L patients underwent a predefined diagnostic evaluation of FD multiorgan involvement. This late-onset phenotype was characterized by common and/or potentially severe cardiac manifestations (left ventricular hypertrophy 40.8%, atrial fibrillation 5%, non-sustained ventricular tachycardia 12.5%, atrioventricular block 18.3%, bifascicular block 13.4%). Extracardiac manifestations included albuminuria>30 mg/24 h 36.1%, chronic kidney disease≥G3 7.6%, brain white matter lesions 54.4%, stroke 3.3%, sensorineural deafness 44.5%, cornea verticillata 13.9%. Plasma lyso-GB3 was undetectable in females, regardless of clinical manifestations. A founder effect of FD due to p.F113L mutation was documented by genealogy and genetics in a Portuguese region. In this late-onset phenotype, although cardiac manifestations carry the highest prognostic impact, extracardiac involvement is common. Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Citation

Olga Azevedo, Andreas Gal, Rui Faria, Paulo Gaspar, Gabriel Miltenberger-Miltenyi, Miguel F Gago, Fátima Dias, Alice Martins, Jorge Rodrigues, Pedro Reimão, Olga Pereira, Sónia Simões, Emilia Lopes, Maria José Guimarães, Nuno Sousa, Damião Cunha. Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype. Molecular genetics and metabolism. 2020 Feb;129(2):150-160